The growth of Viagra and its impact on the medicinal landscape presents a intricate question for investors. While the early sales data were impressive, the exclusivity has ended, leading to a deluge of off-brand alternatives that are eroding profit. In addition, the industry is facing challenges related to demographic trends and shifting healthcare